102 related articles for article (PubMed ID: 21183764)
1. Platelet resistance - much known and much more unknown.
Dieter RS; Lopez JJ; Nanjundappa A
J Invasive Cardiol; 2011 Jan; 23(1):14. PubMed ID: 21183764
[No Abstract] [Full Text] [Related]
2. A randomized pilot trial for aggressive therapeutic approaches in aspirin-resistant patients undergoing percutaneous coronary intervention.
El-Atat F; Sarkar K; Kodali V; Karajgikar R; Jakkulla M; Mares A; Sharma S; Kini A
J Invasive Cardiol; 2011 Jan; 23(1):9-13. PubMed ID: 21183763
[TBL] [Abstract][Full Text] [Related]
3. The future of an illusion.
Bittl JA
J Am Coll Cardiol; 2006 Jun; 47(12):2380-3. PubMed ID: 16781362
[No Abstract] [Full Text] [Related]
4. Antithrombotic therapy to support primary PCI.
Morrow DA
N Engl J Med; 2008 May; 358(21):2280-2. PubMed ID: 18499573
[No Abstract] [Full Text] [Related]
5. ACUITY-PCI: one drug does not fit all.
Waksman R
Lancet; 2007 Mar; 369(9565):881-2. PubMed ID: 17368130
[No Abstract] [Full Text] [Related]
6. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
7. Provisional use of glycoprotein IIb/IIIa inhibitors in the era of dual antiplatelet therapy--do "bailouts" pay off?
Jeremias A; Gruberg L
J Invasive Cardiol; 2009 Jun; 21(6):264-5. PubMed ID: 19494401
[No Abstract] [Full Text] [Related]
8. Antithrombotic benefits and hemorrhagic risks of direct thrombin antagonists.
Harker LA; Hanson SR; Kelly AB
Thromb Haemost; 1995 Jul; 74(1):464-72. PubMed ID: 8578508
[No Abstract] [Full Text] [Related]
9. Direct thrombin inhibitors for percutaneous coronary intervention in the current era of platelet glycoprotein IIb/IIIa inhibition.
Reginelli JP; Chew D
J Interv Cardiol; 2002 Apr; 15(2):141-6. PubMed ID: 12063809
[No Abstract] [Full Text] [Related]
10. Contemporary use of antiplatelet therapies in percutaneous coronary interventions.
Saw J; Moliterno DJ
Coron Artery Dis; 2003 Aug; 14(5):373-80. PubMed ID: 12878902
[No Abstract] [Full Text] [Related]
11. An overview of antithrombins in peripheral vascular interventions.
Shammas NW
J Invasive Cardiol; 2004 Aug; 16(8):440-3. PubMed ID: 15282423
[No Abstract] [Full Text] [Related]
12. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial.
Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ
Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845
[TBL] [Abstract][Full Text] [Related]
13. HORIZONS-AMI.
Webster MW
Lancet; 2010 Jan; 375(9712):375. PubMed ID: 20113821
[No Abstract] [Full Text] [Related]
14. Glycoprotein IIb/IIIa inhibitors: do they still have a role?
Bhatt DL
J Am Coll Cardiol; 2011 Mar; 57(10):1200-1. PubMed ID: 21371636
[No Abstract] [Full Text] [Related]
15. It is standard practice, but is it really best practice or clinical biocreep?
Gilchrist IC
Catheter Cardiovasc Interv; 2010 Oct; 76(4):525-6. PubMed ID: 20882656
[No Abstract] [Full Text] [Related]
16. Provisional glycoprotein IIb/IIIa blockade in a randomized investigation of bivalirudin versus heparin plus planned glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: predictors and outcome in the Randomized Evaluation in Percutaneous coronary intervention Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Exaire JE; Butman SM; Ebrahimi R; Kleiman NS; Harrington RA; Schweiger MJ; Bittl JA; Wolski K; Topol EJ; Lincoff AM;
Am Heart J; 2006 Jul; 152(1):157-63. PubMed ID: 16824849
[TBL] [Abstract][Full Text] [Related]
17. Impact of bivalirudin on outcomes after percutaneous coronary revascularization with drug-eluting stents.
Feldman DN; Wong SC; Gade CL; Gidseg DS; Bergman G; Minutello RM
Am Heart J; 2007 Oct; 154(4):695-701. PubMed ID: 17892994
[TBL] [Abstract][Full Text] [Related]
18. Platelet reactivity and percutaneous coronary intervention: another clue in the quest for the Holy Grail of tailored antithrombotic therapy?
Di Sciascio G; Mangiacapra F
J Am Coll Cardiol; 2012 Jul; 60(5):378-80. PubMed ID: 22682552
[No Abstract] [Full Text] [Related]
19. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions.
Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS
Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428
[TBL] [Abstract][Full Text] [Related]
20. Accounting for ACUITY.
Bittl JA
N Engl J Med; 2006 Nov; 355(21):2249-50. PubMed ID: 17124024
[No Abstract] [Full Text] [Related]
[Next] [New Search]
